Hodgkin lymphoma, version 2.2015.
J Natl Compr Canc Netw
; 13(5): 554-86, 2015 May.
Article
em En
| MEDLINE
| ID: mdl-25964641
ABSTRACT
Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doença de Hodgkin
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article